Founded in 2014, Edinburgh Molecular Imaging (EM Imaging) is a clinical phase biotechnology company focused on enabling image guided interventional medicine.
The company’s molecular targetting technology has the potential to target disease in real-time to allow interventional procedures including surgery and therapy, providing more accurate treatment while sparing healthy tissue.
The focus of EM Imaging is the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes or radionucleides, target and specifically bind with cancerous cells and other diseased tissue. This provide the clinician with a clearer view of the extent of disease and thus a decision-making tool to benefit the patient.
The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, radiochemistry, biochemistry and cell biology, along with direct clinical expertise. The team also has significant expertise in the clinical development, approval and reimbursement of molecular imaging and therapeutic agents.
EM Imaging plans to become a leader in offering targeted fluorescent optical imaging and therapy agents as a cost effective and accessible imaging modality.